Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.
The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.
The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。